Brasília – Daniela Marreco, now serving as director at Anvisa, emphasized that her mandate will focus on reducing regulatory backlogs and positioning the agency as a driver of innovation in health technologies.

A career official at Anvisa since 2006, with experience as executive secretary of CMED, Marreco highlighted that strategies such as regulatory reliance, regulatory sandbox, and the use of artificial intelligence will be key to improving analysis timelines and aligning Anvisa with innovation policies.

She also pointed to the need to revise regulations for AI-based software and medical devices, incorporating international benchmarks to guide the agency’s approach.

On clinical trials, Marreco underscored that Anvisa actively participated in drafting Law 14.874/2024 and will work with relevant bodies to ensure deadlines are compatible with the agency’s operational capacity.

Source: Futuro da Saúde

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com